CTOs on the Move

University HealthSystem Consortium

www.uhc.edu

 
UHC, based in Oak Brook, Ill., and representing 0.7 of the academic medical centers in the United States, is an alliance of 84 academic medical centers and 80 associate members.
  • Number of Employees: 1K-5K
  • Annual Revenue: $0-1 Million
  • www.uhc.edu
  • 2001 Spring Rd Ste 700
    Oak Brook, IL USA 60523-1890
  • Phone: 630.954.1700

Executives

Name Title Contact Details

Similar Companies

Physicians Health Choice

Physicians Health Choice is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Baby and Me Fitness

Baby and Me Fitness is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioStorage Technologies Inc

BioStorage Technologies Inc is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The FlexPro Group

Founded by identical twins, Rose Cook and Lynn Faughey, The FlexPro Group is a specialty consulting firm, focused on delivering project management expertise to companies in the Life Sciences. Since 2008, FlexPro has been recognized as a premier provider of project management consulting services to this industry. For the 3rd year in a row, FlexPro was recognized by Inc. Magazine as one of America`s fastest-growing private companies: #859 (2014), #288 (2013) and #104 (2012). Also ranked 6th on the Philadelphia 100 lists of fastest growing privately-held companies (both in 2013 and 2012). Ranked among the Top 25 Management Consulting Firms in Philadelphia Business Journal`s "The List" (2017).

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.